"FDA" agrees to use cell therapy for leukemia

The US Food and Drug Administration, “FDA”, said on Monday that it had agreed to use cell therapy produced by Gamida Cell to reduce the risk of infection in patients undergoing leukemia, leading the company’s shares to 46%. Approval of the use of treatment would enable the business to launch its first commercial treatment under the name “OmiSirge” for patients from the age of 12, and they undergo stem cell transplantation. Before the transplantation, patients often undergo radiation or chemotherapy, which can weaken their immune system and expose it to the risk of serious infection that can sometimes cause their lives. The company said earlier that it was aimed at treating about 2500 patients annually by 2027, but that kept them from commenting on the price that provided treatment or its availability. “Today’s approval is an important progress with stem cell therapy for patients with leukemia.” Said Peter Marx, director of the Food and Drug Administration. He added in a statement issued by the administration: “The acceleration of the return of white blood cells in the body may reduce the possibility of a severe or comprehensive infection associated with stem cell transplantation. This approval reflects the commitment of the ongoing food and medicine section to support the development of innovative life -threatening treatments.” Blood cancer is a form of cancer caused by uncontrolled growth of the cells in the blood, which disrupts the ability of blood cells to perform their normal functions. This abnormal growth of cells often begins in the bone marrow, which consists of stem cells formed in different types of blood cells with specific functions in the body. Blood cancer represents about 10 % of all cancer cases in the United States annually. Blood cancer can be to death, with different survival rates based on various factors, including the specified type of leukemia. This type of cancer can also cause serious and destructive effects on the body, leading to symptoms such as fatigue, leg pain, joints, night sweats, infections, weakness, weight loss and fever. System transplant is a common treatment for blood cancer. The status of healthy stem cells in the body includes restoring normal production and functions of blood cells. One of the sources of healthy stem cells is the blood of the umbilical cord. Generally, the patient is subject to a treatment cycle before this type of transplant to remove its stem cells and equip the body to the new stem cells. Also read: